ImmunoTools IT-Box-139 Award 2012

Sara Ciceri

PhD Supervisor: Dr. Daniela Perotti

IRCCS Foundation – Istituto Nazionale dei Tumori di Milano
Dept. Of Experimental Oncology – U.O.4
Via Amadeo, 42 20133 Milan Italy

Role of inflammation in Papillary Thyroid Carcinoma

Epidemiological evidence firmly supports a link between chronic inflammation and cancer initiation and progression that occurs in various organs. Papillary Thyroid Carcinoma (PTC) represents a clear example of this process. In PTC there is a strong cross-talk between tumor and the infiltrating immune cells (such as TAM, CD4+, CD3+, CD8+. CD20+ etc...). Moreover, PTC cells are able to produce mediators of inflammation that modulate and control immune cell behavior and also have an autocrine effect on tumor cells.
I started my PhD one year ago and actually I'm characterizing a cellular model of PTC (TPC-1 cell line) regarding its ability to produce small soluble mediators of inflammations (for example the production of IL6) and their relative receptors (e.g. CD126/CD130/CD44/CD56 etc...).
The IT-Box-139 could be give me a panbel of Ab useful for the characterization of the cell surface complexity of TPC-1 and, moreover, could help me in my experiments with the new live-imanging microscope (departmental instrument). With this technology combined with a big panel antibodies I could follow the interaction between soluble mediators and their receptors and so I could dissect the molecular mechanism and the importance of these inflammation components in PTC.

ImmunoTools IT-Box-139 for Sara Ciceri include 100 antibodies

FITC - conjugated anti-human CD1a, CD3, CD4, CD5, CD6, CD7, CD8, CD14, CD15, CD16, CD19, CD21, CD25, CD29, CD35, CD36, CD41a, CD42b, CD45, CD45RA, CD45RB, CD45RO, CD49d, CD53, CD57, CD61, CD63, CD80, CD86, HLA-DR, IL-6, Control-IgG1, Control-IgG2a, Control-IgG2b, Annexin V

PE - conjugated anti-human CD3, CD4, CD8, CD11b, CD15, CD14, CD18, CD19, CD20, CD21, CD22, CD31, CD33, CD38, CD40, CD45, CD45RB, CD50, CD52, CD56, CD58, CD62p, CD72, CD95, CD105, CD147, CD177, CD235a, HLA-ABC, IL-6, Control-IgG1, Control-IgG2a, Control-IgG2b, Annexin V

PE/Dy647 -tandem conjugated anti-human CD3, CD4, CD8, CD14, CD19, CD20, CD25, CD54

APC -conjugated anti-human CD2, CD3, CD4, CD8, CD10, CD11a, CD11c, CD14, CD16, CD27, CD37, CD42b, CD44, CD45, CD59, CD62L, CD69, CD71, IL-6, Control-IgG1, Control-IgG2a, Control-IgG2b, Annexin V

DETAILS